

Important publications of meeting proceedings

- Walsh JW, Wanner A. Quantitative chest tomography in COPD research. Proc Amer Thor Soc 2008; 9:873-945
<https://www.atsjournals.org/toc/pats/5/9>
- Wanner A, De Arce A, Pardee E. Novel therapeutic uses of alpha-1 antitrypsin: A window to the future. J COPD 2012; 9:1-6
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Novel+therapeutic+uses+of+alpha-1+antitrypsin%3A+A+window+to+the+future>
- Wanner. A et al. Clinical trial design for alpha-1 antitrypsin deficiency: A model for rare diseases. J COPD F 2015; 2: 112-156
<https://www.ncbi.nlm.nih.gov/pubmed/28848840>
- Teckman J et al. Appropriateness of newborn screening for alpha-1 antitrypsin deficiency. J Pediatr Gastroenterol Nutr 2014; 58: 199-203
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Appropriateness+of+newborn+screening+for+alpha-1+antitrypsin+deficiency>
- Wanner A et al. Can cystic fibrosis and alpha-1 antitrypsin deficiency inform COPD? Ann Am Thor Soc 2016; 13: 112- 198
https://www.atsjournals.org/toc/annalsats/13/Supplement_2
- Lomas D et al. Protein misfolding and obstructive lung disease. Proc Amer Thor Soc 2010; 7: 343-415
<https://www.ncbi.nlm.nih.gov/pubmed/21030512>
- Wanner A et al. Novel Concepts in the Mechanisms, Monitoring and Treatment of COPD in Alpha-1 Antitrypsin Deficiency. Ann Amer Thor Soc 2016; Vol 13, Supplement 4, p S279, Aug 2016
https://www.atsjournals.org/toc/annalsats/13/Supplement_4
- Coors M et al. Ethical considerations in clinical trials in rare diseases. Trans Sci Rare Dis 2017; 2: 175-194
<https://content.iospress.com/articles/translational-science-of-rare-diseases/trd013>
- Brantly M et al. MZ carrier state in alpha-1 antitrypsin deficiency: Summary of the 16th Gordon L.Snyder Critical Issues Workshop. Trans Sci Rare Dis 2018; 3: 105-120
- Wanner A. Why publish scientific meeting proceedings? Summary of the 2017 International Conference on Alpha-1 Antitrypsin. Chron Obstr Pulm Dis 2018; 5: 231-232